#MedSky🧪 #Clinicaloncology The new bispecific Rx #ivonescimab has outperformed #PD1checkpointinhibitor Keytruda (pembrolizumab) in a head-to-head #clinicaltrial of NSCLC . The dual-action #VEGF–PD-1 antibody nearly doubled progression-free survival over the PD-1 blocker
rdcu.be/dW0kn
4
2
1
0